# NMI Package Development Roadmap üöÄ

**Author:** Ahmad Sofi-Mahmudi  
**Email:** a.sofimahmudi@gmail.com  
**Branch:** develop  
**Version:** 1.1.0+  
**Year:** 2025

---

## üìã **Current State Analysis**

### ‚úÖ **What NMI v1.0.0 Currently Provides:**
- Network Meta-Interpolation for binary effect modifiers
- BLUP-based imputation for missing subgroup data
- Bayesian framework using Stan
- Support for binary, continuous, and count outcomes
- Interactive Shiny application
- Professional HTML reporting
- Comprehensive documentation and vignettes

### üîç **Identified Limitations from Literature Review:**

1. **Effect Modifier Types**: Currently limited to binary/categorical effect modifiers
2. **Data Requirements**: Requires subgroup data for all studies and EM levels
3. **Correlation Structure**: Assumes identical correlation between EMs across studies
4. **Network Connectivity**: Limited to connected networks, cannot include single-arm studies
5. **Real-World Data**: No integration with RWD alongside trial data
6. **Continuous Covariates**: Cannot handle purely numeric covariates directly

---

## üéØ **Strategic Development Priorities**

### **Phase 1: Core Methodology Extensions (v1.1.0)**

#### 1.1 **Enhanced Effect Modifier Support**
- **Continuous Effect Modifiers**
  - Implement spline-based interpolation for continuous covariates
  - Add discretization strategies with overparameterization safeguards
  - Develop adaptive binning algorithms
  
- **Mixed Effect Modifier Types**
  - Support networks with both binary and continuous EMs
  - Flexible specification of EM types per study
  - Interaction modeling between different EM types

- **Implementation Priority**: High üî¥
- **Complexity**: Medium
- **Timeline**: 3-4 months

#### 1.2 **Robust Imputation Methods**
- **Advanced BLUP Alternatives**
  - Multiple imputation with uncertainty quantification
  - Machine learning-based imputation (Random Forest, Neural Networks)
  - Bayesian imputation with informative priors
  
- **Missing Data Patterns**
  - Handle studies with partial subgroup reporting
  - Sensitivity analysis for missing data assumptions
  - Pattern mixture models for non-ignorable missingness

- **Implementation Priority**: High üî¥
- **Complexity**: High
- **Timeline**: 4-5 months

#### 1.3 **Flexible Correlation Structures**
- **Study-Specific Correlations**
  - Allow varying correlation patterns across studies
  - Hierarchical modeling of correlation structures
  - Robust estimation with limited data
  
- **External Correlation Sources**
  - Integration of external correlation estimates
  - Meta-analytic pooling of correlation data
  - Sensitivity analysis across correlation ranges

- **Implementation Priority**: Medium üü°
- **Complexity**: High
- **Timeline**: 3-4 months

---

### **Phase 2: Network Extensions (v1.2.0)**

#### 2.1 **Disconnected Networks Support**
- **Single-Arm Studies Integration**
  - Power prior models for RWD incorporation
  - Borrowing fraction estimation
  - Bias adjustment methods
  
- **Network Bridging**
  - Indirect connections via shared patient characteristics
  - Propensity score matching across studies
  - Synthetic control methods

- **Implementation Priority**: High üî¥
- **Complexity**: Very High
- **Timeline**: 6-8 months

#### 2.2 **Real-World Data Integration**
- **Mixed Evidence Networks**
  - RCT + RWD synthesis methods
  - Quality weighting schemes
  - Bias adjustment frameworks
  
- **Observational Study Support**
  - Confounding adjustment methods
  - Causal inference frameworks
  - External validity assessment

- **Implementation Priority**: Medium üü°
- **Complexity**: Very High
- **Timeline**: 8-10 months

---

### **Phase 3: Advanced Analytics (v1.3.0)**

#### 3.1 **Precision Medicine Applications**
- **Personalized Treatment Effects**
  - Individual-level effect prediction
  - Biomarker-driven subgroup identification
  - Treatment recommendation algorithms
  
- **Dynamic Treatment Regimes**
  - Multi-stage treatment decisions
  - Adaptive randomization support
  - Optimal treatment sequences

- **Implementation Priority**: Medium üü°
- **Complexity**: Very High
- **Timeline**: 10-12 months

#### 3.2 **Advanced Outcomes Support**
- **Time-to-Event Outcomes**
  - Survival analysis integration
  - Competing risks models
  - Cure fraction models
  
- **Multivariate Outcomes**
  - Joint modeling of multiple endpoints
  - Benefit-risk assessment
  - Quality-adjusted life years (QALYs)

- **Implementation Priority**: Medium üü°
- **Complexity**: High
- **Timeline**: 6-8 months

#### 3.3 **Causal Inference Integration**
- **Directed Acyclic Graphs (DAGs)**
  - Automated confounder identification
  - Causal pathway analysis
  - Mediation analysis support
  
- **Target Trial Emulation**
  - RWD study design principles
  - Immortal time bias correction
  - Selection bias adjustment

- **Implementation Priority**: Low üü¢
- **Complexity**: Very High
- **Timeline**: 12+ months

---

### **Phase 4: Computational Enhancements (v1.4.0)**

#### 4.1 **Performance Optimization**
- **Parallel Computing**
  - Multi-core MCMC sampling
  - Distributed computing support
  - GPU acceleration for large networks
  
- **Scalability Improvements**
  - Memory-efficient algorithms
  - Streaming data processing
  - Large network optimization

- **Implementation Priority**: Medium üü°
- **Complexity**: High
- **Timeline**: 4-6 months

#### 4.2 **Advanced User Interfaces**
- **Enhanced Shiny Application**
  - Real-time analysis monitoring
  - Interactive network visualization
  - Collaborative analysis features
  
- **API Development**
  - RESTful API for integration
  - Python interface (reticulate)
  - Cloud deployment options

- **Implementation Priority**: Medium üü°
- **Complexity**: Medium
- **Timeline**: 3-4 months

---

## üî¨ **Research and Validation Priorities**

### **Real-World Applications**
1. **Oncology Networks**: Immuno-oncology therapy comparisons
2. **Cardiovascular Disease**: SGLT2 inhibitor effectiveness
3. **Mental Health**: Antidepressant treatment networks
4. **Rare Diseases**: Small sample network analysis

### **Methodological Research**
1. **Simulation Studies**: Expanded scenarios with new methods
2. **Benchmark Comparisons**: Against existing methods (ML-NMR, MAIC, STC)
3. **Sensitivity Analysis**: Robustness to assumption violations
4. **Guidelines Development**: Best practice recommendations

### **Software Validation**
1. **Unit Testing**: Comprehensive test coverage (>90%)
2. **Integration Testing**: End-to-end workflow validation
3. **Performance Testing**: Scalability benchmarks
4. **User Testing**: Usability studies with practitioners

---

## üìö **Documentation and Dissemination**

### **Academic Publications**
1. **Methodology Papers**: Core extensions in top journals
2. **Application Studies**: Real-world case studies
3. **Software Papers**: JOSS/JSS submissions
4. **Review Articles**: Comprehensive method comparisons

### **Educational Resources**
1. **Advanced Vignettes**: Step-by-step tutorials
2. **Video Tutorials**: Recorded workshops
3. **Case Study Database**: Exemplar analyses
4. **Best Practice Guidelines**: Implementation recommendations

### **Community Engagement**
1. **Conference Presentations**: ISPOR, SMDM, JSM
2. **Workshops**: Hands-on training sessions
3. **Webinar Series**: Regular methodology updates
4. **User Forum**: Community support platform

---

## üéØ **Success Metrics**

### **Technical Metrics**
- ‚úÖ Code coverage >90%
- ‚úÖ Computational efficiency improvements >50%
- ‚úÖ Memory usage reduction >30%
- ‚úÖ User-reported bug rate <1%

### **Adoption Metrics**
- üìà CRAN downloads >10K/month
- üìà GitHub stars >500
- üìà Academic citations >50
- üìà Industry adoption >10 organizations

### **Quality Metrics**
- üìä User satisfaction >4.5/5
- üìä Documentation completeness >95%
- üìä Method validation studies >5
- üìä Real-world applications >10

---

## ü§ù **Collaboration Opportunities**

### **Academic Partnerships**
- University of Toronto (Biostatistics)
- Cytel Inc (Real World Analytics)
- Various HTA agencies worldwide

### **Industry Collaborations**
- Pharmaceutical companies
- CRO organizations
- Health economics consultancies
- Regulatory agencies

### **Open Source Community**
- Stan Development Team
- R package ecosystem contributors
- Health economics modeling groups
- Clinical trial networks

---

## üí° **Innovation Areas**

### **Emerging Technologies**
- **AI/ML Integration**: Deep learning for pattern recognition
- **Federated Learning**: Privacy-preserving multi-site analysis
- **Blockchain**: Secure data sharing protocols
- **Digital Twins**: Patient simulation models

### **Methodological Innovations**
- **Quantum Computing**: Optimization algorithms
- **Graph Neural Networks**: Network relationship modeling
- **Reinforcement Learning**: Adaptive trial designs
- **Natural Language Processing**: Automated data extraction

---

## üìÖ **Timeline Summary**

| Phase | Version | Timeline | Key Features |
|-------|---------|----------|--------------|
| 1 | v1.1.0 | 3-5 months | Continuous EMs, Advanced imputation |
| 2 | v1.2.0 | 6-10 months | Disconnected networks, RWD integration |
| 3 | v1.3.0 | 10-15 months | Precision medicine, Advanced outcomes |
| 4 | v1.4.0 | 15-20 months | Performance optimization, APIs |

**Total Development Horizon**: 20+ months for comprehensive advancement

---

*This roadmap will be continuously updated based on user feedback, methodological advances, and real-world application experiences.* 